Management Team

Board Members

  • David Wang, MD, Ph.D.


    David Wang, M.D., Ph.D., is a Partner and Senior Managing Director on OrbiMed Asia team, focused on Greater China.

    Previously, he was a Managing Director at WI Harper Group, responsible for healthcare investments in China. He also previously served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. Dr. Wang was a co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, Dr. Wang was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine.

    He received his M.D. from Peking University Medical School and his doctorate in Developmental Biology from the California Institute of Technology.

  • Wei Li, Ph.D.

    Board Director

    Dr. Wei Li is the Founding Partner at Creacion Ventures.

    Before founding Creacion Ventures, Dr. Li served as the management partner in 6 Dimensions Capital, the partner of Fidelity Biotechnology and Fidelity Growth Partners Asia, and the co-founder of Innovent.

    Dr. Wei Li has successfully founded or involved in the founding of a series of biotechnology companies in China and overseas, including Innovent Biologics (stock code: 1801. HK), CStone Pharmaceuticals (stock code: 2616. HK), Ocumension Therapeutics (stock code: 1477. HK), and Dewpoint Therapeutics.

    Dr. Wei Li holds a Ph.D. degree in Biochemistry from Harvard University and an MBA degree from the Northwestern University – Kellogg School of Management.

  • Diyong Xu

    Board Director

    Mr. Diyong Xu is the Principal at Orbimed U.S. and former investment banking analyst at Lazard Freres & Co.

    Mr. Diyong Xu holds a Master of Science (M.S.) degree in Management Science and Engineering from Stanford University, a M.S. degree in Molecular and Cellular Biology from the Dartmouth Medical School, and a Bachelor of Science degree in Biology from the Zhejiang University in China.

  • Kevin Yuan

    Board Director

    Mr. Kevin Yuan is the Chief Executive Officer at Shanghai Hankang Private Equity Management Co., Ltd.

    Mr. Hong Yuanquan has more than 20 years of experience investing in China’s biopharmaceutical industry and has led the investment in over 40 early-stage biopharmaceutical companies, including some that already became industry leaders, such as InnoCare Pharma (9969. HK, 688428. SH), AkesoBio (9926. HK), Keymed Biosciences (2162. HK), Chipscreen Biosciences (688321. SH), Abbisko Therapeutics (2256. HK), and OPM Biosciences (688293. SH).

    Mr. Kevin Yuan holds a Master degree in Management from Zhejiang University and an MBA degree from the China Europe International Business School (CEIBS).

  • Qunsheng Ji, MD, Ph.D.

    Board Director

    Dr. Qunsheng Ji is the Chief Executive Officer at Sirius Therapeutics.

    Prior to Sirius, he was the Vice President and Head of the Oncology and Immunology Unit at Wuxi AppTec, and Head of BioScience and Director of Translational Medicine at Asia & Emerging Market iMed, AstraZeneca.

    Dr. Qunsheng Ji holds a Doctor of Medicine (MD) degree from the First Military Medical University in China, and a Ph.D. degree in Cellular Biology from Vanderbilt University/Peking Union Medical College of the Chinese Academy of Medical Sciences.

  • Douglas Fambrough, Ph.D.

    Independent Director

    Dr. Douglas Fambrough was the Founder, President and Chief Executive Officer of Dicerna Pharmaceuticals (a company that was acquired by Novo Nordisk for US$3.3 billion).

    Dr. Douglas Fambrough holds a Ph.D. degree in Genetics from the University of California, Berkley, and a Bachelor degree in Biology from Cornell University.


Our lead investors have been investing in the global healthcare industry for over 20 years. Their portfolios cover a broad array of therapeutic areas and companies at various stages, from start-ups to large multinational enterprises.

Sirius Therapeutics, Inc., all rights reserved

Privacy Policy|Contact Us